Current research and management of undifferentiated pleomorphic sarcoma/myofibrosarcoma

Undifferentiated pleomorphic sarcoma (UPS), once termed as malignant fibrous histiocytoma, has always been diagnosed exclusively in clinical practice because it lacks any defined resemblance to normal mesenchymal tissue. Although myxofibrosarcoma (MFS) has been separated from UPS due to its fibrobla...

Full description

Saved in:
Bibliographic Details
Published in:Frontiers in genetics 2023-02, Vol.14, p.1109491-1109491
Main Authors: Sun, Haitao, Liu, Jilu, Hu, Fangyuan, Xu, Meng, Leng, Ao, Jiang, Feng, Chen, Kefu
Format: Article
Language:English
Subjects:
Genetics
myxofibrosarcoma
sarcomagenesis
signaling pathways
treatment
undifferentiated pleomorphic sarcoma
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Undifferentiated pleomorphic sarcoma (UPS), once termed as malignant fibrous histiocytoma, has always been diagnosed exclusively in clinical practice because it lacks any defined resemblance to normal mesenchymal tissue. Although myxofibrosarcoma (MFS) has been separated from UPS due to its fibroblastic differentiation with myxoid stroma, UPS and MFS are still identified as a sarcoma group in terms of molecular landscapes. In this review article, we will describe the associated genes and signaling pathways involved in the process of sarcoma genesis and make a summary of conventional management, targeted therapy, immunotherapy, and some novel potential treatments of UPS/MFS. With the progressive advancements in medical technology and a better understanding about the pathogenic mechanism of UPS/MFS in the coming decades, new lights will be shed on the successful management of UPS/MFS.
ISSN:1664-8021
1664-8021
DOI:10.3389/fgene.2023.1109491